Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ALK-Abelló A/S (ALK-B.CO)
Horsholm, DK
ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.40% | -2.79% | +16.73% | +18.49% | +9.22% | +10.86% | +51.23% | +188.74% | +85.11% | +305.49% | +1,399.70% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+14.0% ★ Q1'26: +16.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+46.7% ★ Q1'26: +23.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+17.4% ★ Q1'26: +40.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+26.4% ★ Q1'26: +32.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+20.9% ★ Q1'26: +31.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.1% ★ Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.31× ★ Q1'26: 0.16× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.57B
est: 2.53B (+1.6%)
|
3.01B
est: 2.98B (+1.0%)
|
2.91B
est: 2.94B (-1.0%)
|
2.92B
est: 2.93B (-0.5%)
|
3.27B
est: 3.28B (0.0%)
|
3.49B
est: 3.50B (-0.3%)
|
3.92B
est: 3.88B (+0.9%)
|
4.51B
est: 4.46B (+1.1%)
|
4.82B
est: 5.18B (-6.9%)
|
5.54B
est: 5.55B (-0.2%)
|
6.31B
est: 6.27B (+0.7%)
|
7.23B
7.14B – 7.31B
+15.4% YoY
|
8.20B
8.13B – 8.25B
+13.4% YoY
|
9.26B
9.22B – 9.29B
+12.9% YoY
|
10.28B
10.17B – 10.37B
+11.0% YoY
|
11.27B
11.14B – 11.36B
+9.6% YoY
|
| EBITDA |
573.00M
est: 427.93M (+33.9%)
|
664.00M
est: 503.73M (+31.8%)
|
227.00M
est: 497.21M (-54.3%)
|
154.00M
est: 495.77M (-68.9%)
|
263.00M
est: 554.29M (-52.6%)
|
380.00M
est: 592.85M (-35.9%)
|
544.00M
est: 657.03M (-17.2%)
|
709.00M
est: 755.17M (-6.1%)
|
914.00M
est: 1.09B (-16.1%)
|
1.39B
est: 1.17B (+19.5%)
|
1.98B
est: 1.32B (+50.3%)
|
1.52B
1.50B – 1.54B
+15.4% YoY
|
1.72B
1.71B – 1.73B
+13.4% YoY
|
1.95B
1.94B – 1.95B
+12.9% YoY
|
2.16B
2.14B – 2.18B
+11.0% YoY
|
2.37B
2.34B – 2.39B
+9.6% YoY
|
| EBIT |
414.00M
est: 283.97M (+45.8%)
|
501.00M
est: 334.27M (+49.9%)
|
-106.00M
est: 329.95M (-132.1%)
|
-78.00M
est: 328.99M (-123.7%)
|
8.00M
est: 367.83M (-97.8%)
|
135.00M
est: 393.42M (-65.7%)
|
302.00M
est: 436.01M (-30.7%)
|
471.00M
est: 501.13M (-6.0%)
|
669.00M
est: 814.62M (-17.9%)
|
1.12B
est: 872.49M (+28.6%)
|
1.66B
est: 985.76M (+68.7%)
|
1.14B
1.12B – 1.15B
+15.4% YoY
|
1.29B
1.28B – 1.30B
+13.4% YoY
|
1.46B
1.45B – 1.46B
+12.9% YoY
|
1.62B
1.60B – 1.63B
+11.0% YoY
|
1.77B
1.75B – 1.79B
+9.6% YoY
|
| Net Income |
344.00M
est: 242.86M (+41.6%)
|
270.00M
est: 586.98M (-54.0%)
|
-158.00M
est: -24.64M (-541.3%)
|
-170.00M
est: -80.54M (-111.1%)
|
-50.00M
est: -42.06M (-18.9%)
|
25.00M
est: 80.31M (-68.9%)
|
219.00M
est: 189.84M (+15.4%)
|
335.00M
est: 345.64M (-3.1%)
|
486.00M
est: 711.09M (-31.7%)
|
815.00M
est: 870.35M (-6.4%)
|
1.20B
est: 1.25B (-4.0%)
|
1.44B
1.40B – 1.49B
+15.8% YoY
|
1.64B
1.56B – 1.69B
+13.5% YoY
|
1.86B
1.80B – 1.90B
+13.6% YoY
|
2.33B
2.30B – 2.35B
+25.1% YoY
|
2.95B
2.91B – 2.98B
+26.7% YoY
|
| SGA |
1.03B
est: 933.75M (+10.6%)
|
1.14B
est: 1.10B (+3.7%)
|
1.30B
est: 1.08B (+19.6%)
|
1.36B
est: 1.08B (+26.1%)
|
1.46B
est: 1.21B (+20.4%)
|
1.36B
est: 1.29B (+5.3%)
|
1.47B
est: 1.43B (+2.8%)
|
1.66B
est: 1.65B (+0.6%)
|
1.75B
est: 1.82B (-3.7%)
|
1.93B
est: 1.95B (-0.9%)
|
1.90B
est: 2.20B (-13.8%)
|
2.54B
2.51B – 2.57B
+15.4% YoY
|
2.88B
2.86B – 2.90B
+13.4% YoY
|
3.25B
3.24B – 3.27B
+12.9% YoY
|
3.61B
3.57B – 3.64B
+11.0% YoY
|
3.96B
3.92B – 3.99B
+9.6% YoY
|
| EPS |
1.77
est: 1.10 (+61.5%)
|
1.38
est: 2.65 (-47.9%)
|
-0.80
est: -0.11 (-619.4%)
|
-0.78
est: -0.36 (-114.6%)
|
-0.23
est: -0.19 (-21.1%)
|
0.11
est: 0.36 (-69.7%)
|
1.00
est: 0.86 (+16.7%)
|
1.52
est: 1.56 (-2.6%)
|
2.20
est: 3.21 (-31.5%)
|
3.68
est: 3.93 (-6.4%)
|
5.40
est: 5.63 (-4.1%)
|
6.50
6.30 – 6.70
+15.4% YoY
|
7.33
7.02 – 7.60
+12.9% YoY
|
8.27
8.11 – 8.58
+12.8% YoY
|
10.50
10.35 – 10.61
+26.9% YoY
|
13.30
13.11 – 13.44
+26.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Peter Halling | President, Chief Executive Officer & Member of Management Board | 17M | male |
| Søren Daniel Niegel | Member of Management Board | 12M | male |
| Claus Steensen Solje | Executive Vice President, Chief Financial Officer & Member of Management Board | 8M | male |
| Nanna Rassov Carlson | Senior Manager of QA Release & Employee Representative Director | 400.0K | female |
| Johan Smedsrud | Senior Maintenance Supporter of Process & Production Support & Employee Representative Director | 400.0K | male |
| Lise Lund Maerkedahl | Project Director of Global Clinical Development & Employee-elected Director | 400.0K | female |
| Katja Barnkob Thalund | Senior Project Director, Global Clinical Development & Employee-elected Director | 400.0K | female |
| Lika Thiesen | Executive Vice President of Global People & Organisation | — | female |
| Hendrik Kees Kam Nolte | Senior Vice President of Research & Development - North America and International Markets | — | — |
| Jacob Glenting | Senior Vice President of Global Strategy & Corporate Development | — | male |
| Christian G. Houghton | Executive Vice President of Product Supply | — | male |
| Per Plotnikof | Vice President of Corporate Communications, Investor Relations & Strategic Planning and Head of IR | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALK-B.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
